Life Science Tech Summit: Speaker Interview

Jonathan SheaJon
Vice President, Information Technology
MACROGENICS

Jon is currently the Head of IT at MacroGenics, a pre-commercial biotech, and loves his wife and two girls, technology, fresh powder, and a glass of big red wine – not necessarily in that order. Prior to MacroGenics, Jon was the head of NA Commercial IT at Allergan where he helped drive innovative digital patient, consumer, and customer strategies. He has a strong background in management consulting, having worked across industries as a Director in PwC’s Advisory service. He is intently focused on strategically aligning process, technology, and organization to transform business objectives. Jon graduated from Virginia Tech with a degree in Computer Engineering and is a passionate Hokie football fan.

Jon will be one of the distinguished speakers at the Life Science Tech Summit.

Why is the Life Science Tech Summit important for IT executives?
The summit is a great opportunity to explore how other life science companies are tackling the challenges we all face while offering the chance to network with peers.

What is one thing you hope to learn or discuss with your peers at the Life Science Tech Summit?
What are the key innovation areas companies are investing in while managing core capabilities and risk.

What initiatives are on the horizon for your team in 2017?
Strategic business initiatives, a continued shift to IaaS/Cloud, and information security.

From your perspective, how has the role of a CIO changed?
We’ve moved from infrastructure and operations, to key business partners, to an innovation champions

What are the 3 biggest factors impacting IT in the life science industry?
Changing market conditions are providing excellent opportunities for technology to disrupt current business practices. Cybersecurity remains a huge area of focus. Cloud services provide the ability to shift infrastructure costs and rapidly move to business enablement.

Where do you draw your technology inspiration from?
Innovative companies outside of Life Science – how can we incorporate fast movers in our strategic thinking?